Skip to main content
SpringerLink
Log in

Human papillomavirus types 16 and 18 vaccine (Cervarix™): a guide to its use in the prevention of cervical cancer

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Ceravirx™]. Drugs 2008; 68(3): 359–72

    Article  PubMed  CAS  Google Scholar 

  2. European Medicines Agency. Cervarix suspension for injection (human papillomavirus types 16 and 18 vaccine): summary of prescribing information [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Apr 30]

  3. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0. Lyon: IARC Press, 2004

    Google Scholar 

  4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar 30; 55(2): 74–108

    Article  PubMed  Google Scholar 

  5. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007 Sep 8; 370(9590): 890–907

    Article  PubMed  CAS  Google Scholar 

  6. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 Aug 20; 111(2): 278–85

    Article  PubMed  Google Scholar 

  7. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003 Jan 13; 88(1): 63–73

    Article  PubMed  CAS  Google Scholar 

  8. Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®). Drugs 2006; 66(9): 1263–71

    Article  PubMed  Google Scholar 

  9. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006 Aug 14; 24(33–34): 5937–49

    Article  PubMed  CAS  Google Scholar 

  10. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 Jun 30; 369(9580): 2161–70

    Article  PubMed  CAS  Google Scholar 

  11. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 Nov 13; 364(9447): 1757–65

    Article  PubMed  CAS  Google Scholar 

  12. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 Jun; 40(6): 564–71

    Article  PubMed  Google Scholar 

  13. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 Apr 15; 367(9518): 1247–55

    Article  PubMed  CAS  Google Scholar 

  14. Gall SA, Teixeira J, Wheeler CM, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract no. 4900]. American Association for Cancer Research Annual Meeting Proceedings; 2007 Apr 14–18; Los Angeles (CA)

  15. Harper DM, Dubin G. Sustained HPV-16 and 18 antibody levels through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract]. 15th International Meeting of the European Society for Gynaecological Oncology; 2007 Oct 28–Nov 1; Berlin

  16. Dessy F, David MP, Schuind A, et al. Evaluation of HPV neutralizing antibodies from an extended follow up study through 5.5 years in women vaccinated with GSKs prophylactic cervical cancer candidate vaccine. The HPV Vaccine study group [abstract no. 5B-01]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

  17. David M-P, Hardt K, Tibaldi F, et al. Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by Cervarix™: modelling of sustained antibody responses [abstract no. PS26-37]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

  18. Poncelet S, Cambron P, Giannini SL, et al. Induction of cervical mucosal HPV IgG in women 15–55 years old following systemic vaccination with GSKs prophylactic cervical cancer candidate vaccine. The HPV Vaccine Study Group for Adult Women [abstract no. PS19-25]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

  19. Cruickshank M, Teixeira J, Gall S, et al. Efficacy and safety of GSK’s HPV vaccine in women initially seropositive or seronegative for HPV-16/18 in a phase III trial [abstract no. SS1-2]. European Research Organisation on Genital Infection and Neoplasia; 2007 Oct 4–6; Monte Carlo

  20. Harper DM. HPV vaccines: lessons from clinical trials. The HPV-16/18 VLP vaccine adjuvanted with AS04 [abstract no. TC2-4]. 15th European Research Organisation on Genital Infection and Neoplasia; 2007 Oct 4–6; Monte Carlo

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Human papillomavirus types 16 and 18 vaccine (Cervarix™): a guide to its use in the prevention of cervical cancer. Drugs Ther. Perspect 24, 5–8 (2008). https://doi.org/10.2165/00042310-200824060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824060-00002

Search

Navigation